SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The crypto "crow with knife" ($CAW) is gaining attention, with the community rallying behind its unique meme status and multichain functionality across $SOL, $CRO, $ETH, and $BASE. Community members highlight its deflationary mechanics and organic growth, while also pointing to staking opportunities.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending as the community rallies around the nostalgic Rage Guy meme, anticipating a potential moonshot. Community members emphasize the importance of community building and the enduring appeal of OG memes, viewing $RAGE as a rebellion against the status quo. The community is actively participating in spaces and promoting the coin.

Bounce Token

Bounce Token is experiencing heightened interest as the community anticipates a potential breakout, drawing comparisons to previous rallies. Discussions revolve around promising utility, growing bid sizes, and possible integration with AI, with some community members pointing to bullish technical indicators. Despite some skepticism, there's optimism for a significant run, with attention focused on key price levels.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending amidst mixed sentiments, with some community members expressing frustration over its past performance while others remain optimistic, calling for patience and a focus on long-term potential. Discussions include potential price movements and comparisons to other meme coins. The broader conversation also touches upon the overall state of the crypto market and potential market manipulation.

Pojak watched as the world played hot potato with CTO shit coins. Now, it's his moment. With Pepe's legendary meme power and Wojak's emotional depth, Pojak brings a new level of influence, wealth, and ethics. Born into meme royalty with luxury and wisdom from Pepe and Wojak, he faced hardship when the original developer rugged the project. The community rose up and took control. Pojak was reborn, stronger and more determined.

Pojak

Pojak ($PJ) is trending as the community buzzes about its integration with Phantom Wallet, fueling excitement. Discussions highlight the potential for a breakout and "moon" run, with many claiming bags are loaded. Some users suggest caution, comparing it to other hyped coins.

MLN is the official token of Enzyme. Founded in 2017, Enzyme is the global infrastructure for tokenized finance. Enzyme provides industry leaders with a comprehensive suites of Vault-As-A-Service and Financial Instruments products to manage on-chain assets efficiently, optimize operational processes, and develop innovative financial strategies tailored to their unique goals and challenges.

Melon

Recent price action and low supply are sparking increased interest in MLN, with some community members drawing comparisons to other coins with explosive growth potential. Conversations revolve around identifying potential entry points and anticipating a significant upward move. Some traders caution about potential pump and dump schemes.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd.

SU Group ($SUGP) is trending due to increased attention on its low float and potential for a short squeeze, with comparisons being made to other Hong Kong-based stocks. The community highlights the company's regained NASDAQ compliance, a substantial new hospital contract, and its expansion into EV infrastructure as key factors driving interest. Some traders mention the stock's high cost to borrow, anticipating a possible breakout.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta ($KTA) is trending amid speculation about its mainnet launch this month and potential Coinbase listing, generating excitement around its anchor technology. The community emphasizes Keeta's potential to connect all blockchains and fiat payment networks with record-breaking speed, positioning it as a competitor to XRP and a disruptor in the financial market. Some users express frustration about the inability to swap keeta on base.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin is trending as the community discusses the project "crow with knife" ($CAW) and its potential impact on CRO. Some investors express frustration with CRO's price action and concerns about its performance relative to other cryptocurrencies, while others remain optimistic, citing potential catalysts and partnerships.

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.

Delcath Systems Inc

$DCTH is trending due to discussions around recent data and future expectations, with community members debating the impact of the CHOPIN trial results and lowered 2025 guidance. Some investors express concern over declining revenue expectations, while others remain optimistic about the PHP platform and potential for growth in immunotherapy applications. The community is also actively discussing potential buyouts and the company's cash position.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Novo Nordisk A/S (NVO) shares slid 3% in the early premarket session on Monday as the Ozempic and Wegovy weight-loss drugmaker snagged a&nbsp;bearish recommendation from a Wall Street firm.&nbsp;Morgan Stanley analyst downgraded&nbsp;<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk stock</a> to ‘Underweight’ from ‘Equal Weight’ and also reduced the price target for the stock to $47 from $59, the excerpts of the note published by The Fly showed. Morgan Stanley’s updated price target implies a nearly 13% downside from the stock’s Friday close.The stock was among the top five trending equity tickers on Stocktwits early Monday. Retail sentiment toward the stock, however, remained ‘extremely bullish’ (76/100), and the message volume on the stream was ‘high.’<figure class="image"><img style="aspect-ratio:619/53;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_29_at_5_23_05_AM_png_5def6a683f.webp" alt="Screenshot 2025-09-29 at 5.23.05 AM.png" width="619" height="53"><figcaption>NVO sentiment and message volume as of 5:20 a.m. ET, Sept. 29 | source: Stocktwits</figcaption></figure>Morgan Stanley attributed its negative thesis on the Danish company to its view that the weight loss prescription growth in the U.S. would slow down amid competitive pressures. According to the firm, this would drive downside revisions to the 2026 and 2027 consensus estimates for Novo Nordisk.&nbsp;Analysts at the firm said the lack of momentum in U.S. prescriptions for Wegovy, Ozempic and Rybelsus makes it cautious on the company's short-term growth profile. Additionally, the analyst noted that the lack of catalysts exacerbates the downside risk profile over the next six months.A New York Times report stated last week that the company was cutting jobs following the profit warning it issued in late July.&nbsp;Novo Nordisk stock has lost over 34% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-analyst-says-i-phone-s-worst-period-in-china-has-passed/chDMvs4R378">Apple Analyst Says ‘iPhone’s Worst Period In China Has Passed’ — The Xiaomi Data That Adds Strength To Bull Case For Cupertino</a>

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Why Wegovy Maker Novo Nordisk’s Stock Is Sliding 3% Premarket Today

Morgan Stanley attributed its negative thesis on the Danish company to its view that the weight loss prescription growth in the U.S. would slow down amid competitive pressures.

Equity

Morgan Stanley attributed its negative thesis on the Danish company to its view that the weight loss prescription growth in the U.S. would slow down amid competitive pressures.



NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain

NVO rose about 4% on Aug. 18, 2025, after Wegovy won FDA approval as the first GLP-1 therapy for MASH, expanding its reach beyond obesity and diabetes. NVO-heavy ETFs like OZEM, THNR and PPH should benefit from this trend. 

ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data

LLY tumbles despite solid Q2 results. ETFs like IHE, PPH, MEDX and MEDI with top exposure may offer buy-the-dip opportunities.

ETFs to Capitalize on the Novo Nordisk-Septerna Deal

Eli Lilly shares rose more than 1% premarket Thursday, on track to hit levels last seen in late October, as the pharmaceutical giant posted stronger-than-expected earnings and revenue despite another sales miss for its obesity and diabetes drugs.The company reported Q4&nbsp;earnings per share (EPS) of $5.32, beating the $5.08 consensus estimate, while revenue came in at $13.53 billion, topping Wall Street’s $13.43 billion forecast.&nbsp;Sales of its blockbuster GLP-1 drugs Zepbound and Mounjaro surged but came in slightly below expectations, weighed down by lower realized prices.&nbsp;Mounjaro generated $3.53 billion in revenue, a 60% jump from the prior year but short of analysts’ $3.62 billion estimate. Zepbound posted $1.91 billion in sales, missing the $1.98 billion forecast.&nbsp;This marks the second consecutive quarter where both drugs have fallen short of estimates, according to <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/02/06/eli-lilly-lly-earnings-q4-2024.html">CNBC</a>.Older diabetes medicines outperformed expectations, helping offset the shortfall in Lilly’s newer treatments.&nbsp;CEO David Ricks called 2024 a highly successful year, highlighting major clinical readouts for tirzepatide in treating chronic diseases tied to obesity, billions in manufacturing expansion, and the launch of Alzheimer’s drug Kisunla and dermatitis medication Ebglyss as key drivers of long-term growth.&nbsp;“We enter 2025 with tremendous momentum and look forward to strong financial performance and several important Phase 3 readouts which, if positive, will further accelerate our long-term growth,” he added.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Eli_Lilly_sentiment_and_message_volume_Feb_6_premarket_0e4b15d3e8.png" alt="Eli Lilly sentiment and message volume Feb 6 premarket.png" width="1318" height="324"><figcaption>Eli Lilly sentiment and message volume Feb 6 premarket as of 8 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, Eli Lilly was among the top 10 trending tickers ahead of Thursday’s opening, with sentiment turning more bullish.&nbsp;Optimistic traders pointed to the earnings beat and expected continued strength, with one eyeing a move past $900.&nbsp;<stembedurl>https://stocktwits.com/Zukio/message/603106677</stembedurl>Another said hedge funds and institutional investors would likely drive the&nbsp;actual move during market hours.<stembedurl>https://stocktwits.com/nat9co/message/603108641</stembedurl>For 2025, Eli Lilly expects EPS between $22.50 and $24.00, compared to the $22.69 consensus estimate, and projects revenue between $58 billion and $61 billion, surpassing Wall Street’s $58.91 billion forecast.&nbsp;The company is ramping production to meet soaring demand, estimating it will manufacture at least 1.6 times the number of incretin doses in the first half of 2025 compared to a year ago.&nbsp;Lilly also announced plans to report late-stage data for its next-generation obesity drug retatrutide later this year, ahead of schedule.As of Wednesday’s close, <a href="https://stocktwits.com/symbol/LLY">Eli Lilly’s stock</a> was up nearly 8% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Eli Lilly and Company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Eli Lilly's Blockbuster Obesity Drugs Miss Sales Estimates Again, But Investors Cheer Q4 Earnings Beat

Older diabetes medicines outperformed expectations, helping offset the shortfall in Lilly’s newer treatments.

Roundhill Investments Surpasses $4 Billion AUM Milestone

Roundhill Investments Surpasses $4 Billion AUM Milestone Roundhill Investments Surpasses $4 Billion AUM Milestone PR Newswire NEW YORK, Jan. 16, 2025 NEW YORK, Jan. 16, 2025 /PRNewswire/ -- Roundhill...

Eli Lilly &amp; Co. (LLY) shares rose 0.3% premarket Wednesday, bouncing slightly after Tuesday's steep 6%&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lly-stock-falls-on-q4-weight-loss-drug-sales/chG8mwrRVc">plunge</a> — the worst session for the stock in nearly four years.&nbsp;The selloff followed the drugmaker's disappointing fourth-quarter (Q4) revenue guidance, with significant misses in sales for its blockbuster weight-loss and diabetes drugs, Mounjaro and Zepbound.However, several Wall Street analysts expressed optimism, suggesting the dip could offer an attractive entry point for investors.Leerink noted Lilly lowered its Q4 revenue guidance by 5% but issued a 2025 revenue forecast 2% above its consensus, according to The Fly. The brokerage maintained its 'Outperform' rating, citing long-term growth potential and a promising pipeline.BofA Securities reiterated a 'Buy' rating with a $997 price target,&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.investing.com/news/stock-market-news/eli-lilly-bofa-says-buy-the-dip-after-shares-slide-on-q4-miss-3813128">according</a> to Investing.com. Analyst Tim Anderson emphasized that despite short-term challenges, Lilly remains a dominant player in the "diabesity" market with significant growth opportunities.JPMorgan's Chris Schott reportedly called the stock dip following the Q4 sales miss a buying opportunity, highlighting Lilly's strong 2025 positioning, expanded market presence, and anticipated 60% growth in sellable doses of incretins in the first half of 2025.Mizuho's Jared Holz&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.google.com/search?q=eli+lilly+mizuho&amp;oq=eli&amp;gs_lcrp=EgZjaHJvbWUqBggAEEUYOzIGCAAQRRg7MgYIARBFGDsyBggCEEUYOzITCAMQLhiDARjHARixAxjRAxiABDIGCAQQRRg5MgYIBRBFGDwyBggGEEUYPDIGCAcQRRg90gEINjAxMGowajeoAgCwAgA&amp;sourceid=chrome&amp;ie=UTF-8">told</a> CNBC that "some of the supply commentary from the company makes a lot of sense" and highlighted the nascent stage of the obesity market. However, he flagged valuation as a concern, with Lilly trading at 32 times 2025 earnings estimates—higher than most large-cap pharma peers.Retail message volume on Stocktwits about Lilly jumped over 240% on Tuesday.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/LLY_sentiment_and_message_volume_Jan_15_premarket_8c6741e2bb.png" alt="LLY sentiment and message volume Jan 15 premarket.png" width="1318" height="324"><figcaption>LLY sentiment and message volume Jan 15 premarket as of 8 am ET | source: Stocktwits</figcaption></figure>Heading into Wednesday, sentiment on the platform remained 'bullish,' as watchers took cues from analyst optimism and kept faith in long-term prospects for Lilly's weight-loss and diabetes drugs remain intact.<a href="https://stocktwits.com/symbol/LLY">Eli Lilly's stock</a> is down 4.5% year-to-date but has gained over 16% in the past 12 months. The company will report fourth-quarter and full-year results next month.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Eli Lilly Gets Wall Street Backing After Tuesday’s Turmoil, Stock Rises Premarket As Retail Stays Bullish

JPMorgan's Chris Schott reportedly called the stock dip following the Q4 sales miss a buying opportunity.

Eli Lilly Recovers Premarket As Analysts Defend Stock After Tuesday’s Slide, Retail Bullish

Shares of Eli Lilly &amp; Co. dropped over 7% on Tuesday morning, reaching levels last seen in late November and marking the&nbsp;stock’s worst day since March 15, 2021.&nbsp;The decline followed a disappointing fourth-quarter revenue outlook update, particularly from its blockbuster weight-loss and diabetes drugs, Mounjaro and Zepbound.The company now forecasts full-year revenue of about $45 billion, down from its previous range of $45.4 billion-$46 billion and below the consensus of $45.55 billion.&nbsp;Fourth-quarter revenue is expected to be approximately $13.5 billion, falling short of the $13.93 billion consensus.&nbsp;Sales of Mounjaro totaled $3.5 billion, below the $4.4 billion estimate, while Zepbound brought in $1.9 billion, missing expectations of $2.14 billion.CEO David A. Ricks attributed the shortfall to slower-than-expected growth in the U.S. incretin market, compounded by lower year-end channel inventory. Incretins like GLP-1 are used in diabetes and obesity drugs such as Mounjaro and Zepbound.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/LLY_sentiment_and_message_volume_Jan_14_082f836502.png" alt="LLY sentiment and message volume Jan 14.png" width="1318" height="324"><figcaption>LLY sentiment and message volume Jan 14 as of 12:15 pm ET | source: Stocktwits</figcaption></figure>However, retail sentiment on Stocktwits stayed ‘extremely bullish,’ with the ticker climbing to the top five trending symbols list amid a spike in message volume.&nbsp;Many retail investors considered the dip an overreaction, expressing optimism for 2025 projections and hinting they were buying the dip.<stembedurl>https://stocktwits.com/ChrisH76/message/599965534</stembedurl><stembedurl>https://stocktwits.com/NastyPelosi/message/599965487</stembedurl><stembedurl>https://stocktwits.com/OldFagGuy/message/599960901</stembedurl><stembedurl>https://stocktwits.com/JackCoLu/message/599959582</stembedurl>Lilly expects continued growth for Mounjaro and Zepbound in 2025, supported by expanded manufacturing capacity and new market launches.&nbsp;The company plans to increase production of tirzepatide by at least 60% in the first half of 2025 compared to the same period in 2024.Lilly anticipates revenue contributions from new drugs, including oncology treatment Jaypirca, dermatitis medication Ebglyss, Crohn’s disease therapy Omvoh, and Alzheimer’s drug Kisunla.&nbsp;Additionally, the company is pursuing approvals for new indications of existing medicines and potential launches, such as imlunestrant for metastatic breast cancer.Lilly expects its experimental weight-loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-01-13/lilly-sees-new-weight-loss-pill-approval-in-early-2026-ceo-says?sref&amp;">revealed</a> during an interview with Bloomberg TV at the JPMorgan Healthcare Conference in San Francisco on Monday. Data on the pill is expected by mid-2025.Lilly’s stock has gained over 16% in the past year but is down nearly 5% in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mounjaro manufactured by Eli Lilly and Company packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on April 9, 2024. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Eli Lilly Stock Faces Worst Day In Nearly 4 Years On Q4 Weight-Loss Drug Sales Miss, But Retail Bullish On 2025 Projections

The pharma giant expects continued growth for Mounjaro and Zepbound this year, supported by expanded manufacturing capacity and new market launches.  

Shares of Eli Lilly &amp; Co. (<a class="mention" data-mention="$LLY" data-symbol-id="LLY" href="https://stocktwits.com/symbol/LLY" target="_blank">$LLY</a>) and Novo Nordisk A/S (<a class="mention" data-mention="$NVO" data-symbol-id="NVO" href="https://stocktwits.com/symbol/NVO" target="_blank">$NVO</a>) climbed in Tuesday’s premarket trading after the Biden administration announced a proposal to provide Medicare and Medicaid coverage for obesity drugs.In a statement released early Tuesday, the White House said, "The proposed rule would be implemented at the same time as a comprehensive agenda to lower the costs of drugs, including the drug price negotiation program and increased market competition."An analysis by the Department of Health and Human Services (HHS) found that obesity drug pricing in the international market is much lower than in the U.S., the&nbsp; White House release said.&nbsp;"It’s unacceptable that Americans – especially those without insurance coverage for these drugs — are forced to pay so much more for life-saving medications," it added.Currently, anti-obesity medications are given Medicare and Medicaid coverage&nbsp;only&nbsp;for certain conditions like diabetes.&nbsp;"Today’s new proposal would expand access to these innovative medications for obesity, which is widely recognized as a disease, and help an estimated 3.4 million Americans with Medicare," the release said.The Biden administration expects the coverage to reduce out-of-pocket costs of these prescription drugs by as much as 95% for some enrollees. It sees about 4 million adult Medicaid enrollees to gain new access to these medications.The new proposal will override the previous legislation passed 20 years ago, prohibiting Medicare coverage for weight-loss drugs.The proposal has to be endorsed by the incoming Trump administration to become a law.&nbsp; The proposition looks&nbsp;like&nbsp;a tall order as President-elect Donald Trump has nominated&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-names-anti-vaxxer-robert-kennedy-as-health-and-human-services-secretary-here-s-what-it-means-for-healthcare-stocks/cJ4F4ofRfY">Robert Kennedy Jr.</a>, who is very vocal with his opposition to these medications, to lead HHS.&nbsp;Novo Nordisk and Lilly are leaders in the weight-loss drug category, with their Wegovy and Zepbound, respectively. Both are injectable formulation of drugs belonging to a class of medications called GLP-1 agonists. These work by reducing the appetite, slowing the release of food from the stomach and increasing the feeling of fullness after eating.&nbsp;Novo Nordisk’s Wegovy sales jumped 79% year-over-year in the third quarter to $2.5 billion and Lilly’s Zepbound sales came in at $1.26 billion.On Stocktwits, retail sentiment toward both Novo Nordisk and Lilly remained stuck at "neutral."In premarket trading, as of 7:48&nbsp;a.m. ET, Novo Nordisk shares climbed 2.62% to $107.30, and Lilly jumped 4.90% to $792.For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/zoom-video-reports-beat-and-raise-q3-2025/cJIWZvyRgq">Zoom Video Stock Slumps Despite Beat-and-Raise Q3 But Retail Stays Connected</a>

The Biden administration expects the coverage to reduce out-of-pocket costs of obesity drugs by as much as 95% for some enrollees.

Eli Lilly, Novo Nordisk Shares Climb Premarket As Biden Administration Mulls Medicare, Medicaid Coverage For Obesity Drugs: Retail Unmoved

The new proposal would expand access to medications for obesity, and help an estimated 3.4 million Americans with Medicare. 

Danish diabetes drug maker Novo Nordisk A/S ($NVO), which shot to prominence with its Wegovy weight-loss drug, reported Wednesday strong sales and earnings growth for the third quarter.Novo Nordisk reported third-quarter net profit 27.30 billion Danish Kroner ($3.92 billion), up 21% year-over-year (Y-o-Y), as sales also rose by a similar magnitude to 71.31 billion Danish Kroner (DKK).&nbsp;The top-line, however, came in below the 72.3 billion DKK-consensus estimate, according to Reuters, amid softer-than-expected diabetes drug sales.Wegovy sales jumped 79% YoY to 17.30 DKK ($2.5 billion), ahead of the 15.9 billion DKK forecast by analysts.Wegovy is a once-weekly injectable formulation of Novo Nordisk’s diabetes drug semaglutide, marketed as Ozempic. It was approved by the FDA in 2021 for chronic weight management in adults with obesity or overweight with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol.Novo Nordisk’s diabetes franchise fetched sales of 47.94 billion DKK, up 13% YoY.Looking ahead, the company said it expects 2024 sales to rise at a currency-neutral rate of 23-27%, and operating profit to grow by 21%-27%.The company is now evaluating a two-drug combo treatment candidate by the name CagriSema, for obesity, and a late-stage readout for the drug is expected later this year.As of 10:53 am ET, the stock fell 1.91% to $108.03.<figure class="image"><a href="https://stocktwits.com/symbol/NVO"><img style="aspect-ratio:646/140;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/nvo_sentiment_0ac0560a3f.png" alt="nvo-sentiment.png" width="646" height="140"></a><figcaption>NVO sentiment and message volume November 6, 2024, &nbsp;as of 10:53 am ET | Source:&nbsp;Stocktwits</figcaption></figure>Retail sentiment toward Novo Nordisk stock was 'bullish' (72/100), with message volume rising to ‘extremely high’ level.A retailer said on the Stocktwits platform that he was buying the dip.<stembedurl>https://stocktwits.com/Sasquamch/message/591414857</stembedurl>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/exact-sciences-reports-double-miss-for-q3/cJ4RtWFR9Y">Exact Sciences Stock Plunges After Q3 Miss, Guidance Cut: Retail Stays Mostly Positive</a>For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;

Novo Nordisk Q3 earnings and revenue climbed by double-digit percentages.

Novo Nordisk Stock Falls Despite Strong Q3 Weight-Loss Drug Sales: Retail Shrugs Off Weakness

: Novo Nordisk’s injectable weight-loss drug Wegovy sales climbed 79% year-over-year but overall sales growth was a touch soft.

Novo Nordisk’s injectable weight-loss drug Wegovy sales climbed 79% year-over-year but overall sales growth was a touch soft.


Roundhill ETF Trust - Roundhill GLP-1 & Weight Loss ETF

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$27.80
Prev Close	$28.24
Open	$27.54
Dividend Yield	N/A
50-Day Moving Average	$26.61
Beta	N/A
Avg. Volume	8,157.24
PE Ratio	N/A

52-Week High	$29.53
52-Week Low	$20.01
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

OZEM
Roundhill GLP-1 & Weight Loss ETF

Feed

News

Sentiment

Fundamentals

Info

Latest OZEM News

OZEMRoundhill GLP-1 & Weight Loss ETF